US venture Cytori Therapeutics Inc. has won limited approval in Japan for its Cytori Cell Therapy for restricted commercial clinical use in knee osteoarthritis, marking another feather in the cap of the country's efforts to expedite the availability of cell and regenerative therapies, and a new revenue stream for the loss-making San Diego-based company.
Nasdaq-listed Cytori's adipose-derived regenerative cell (ADRCs) therapy will initially be available for this use only through the Tokyo Osteoarthritis Clinic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?